Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) traded up 6.3% during mid-day trading on Tuesday . The stock traded as high as $3.41 and last traded at $3.4550. 2,586,184 shares were traded during trading, a decline of 86% from the average daily volume of 18,141,520 shares. The stock had previously closed at $3.25.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. JPMorgan Chase & Co. lowered their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a report on Monday, August 17th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.06.
Get Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Up 7.8%
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same quarter last year, the business posted ($0.41) earnings per share. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current year.
Insider Activity at Recursion Pharmaceuticals
In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the transaction, the director owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. This represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 131,937 shares of company stock valued at $478,874 over the last ninety days. 6.65% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of RXRX. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $31,000. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $41,000. NewEdge Advisors LLC raised its position in Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after buying an additional 2,428 shares during the last quarter. Fund Advisors of America Inc FL acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at approximately $45,000. Finally, Quantbot Technologies LP acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at approximately $61,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
- IBM Just Opened Its Mainframes to Arm—Is the Market Missing the Shift?
- Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding
- NVIDIA Reveals $21 Billion SpaceX Stake: Signal of Confidence or Circular Financing?
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
